To our knowledge, this is the first meta-analysis to study the effect of SGLT2 inhibitors in HFmrEF or HFpEF patients that analyzed extractable data from all of the previously conducted RCTs on this study topic, including DECLARE-TIMI 58, VERTIS CV, SOLOIST-WHF, SCORED, CANONICAL, PRESERVED-HF, EMPERIAL-Preserved, and the 2 most recent large trials – EMPEROR-Preserved and DELIVER. Here, SLC5A2 is linked to hydrops fetalis.